Study of Pravastatin for Prevention of Recurrent Hypertensive disordrs of Pregnancy

Kumasawa Keiichi0 个研究点目标入组 90 人开始时间: 2023年5月11日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1) Those with a history of hypertensive disorders of pregnancy in previous pregnancies
•(2) Those between 13 weeks 0 days and 16 weeks 6 days of pregnancy at the time of informed consent
•(3) Age: Those who are between 18 and 45 years of age at the time of obtaining consent
•(4) Gender : Female
•(5) Those who have received a full explanation of the study and have given written consent of their own free will based on a full understanding of the study
•(6) Those who can make outpatient visits in accordance with the research implementation schedule

•(1) Those diagnosed with antiphospholipid antibody syndrome
•(2) Those with chronic hypertension in pregnancy
•(3) Those with multiple pregnancies
•(4) Those with severe obesity with a BMI of 30 or higher at the time of informed consent
•(5) Those with a history of allergy to aspirin, salicylates, or pravastatin
•(6) Those who have a history of serious drug allergy such as anaphylactic shock or a history of serious side effects
•(7) Those who have participated in clinical research within 17 weeks before obtaining consent and have taken the study drug
•(8) Those with serious hepatic disorder or a history of such disorder
•(9) Those who are alcoholic
•(10) Those with chronic kidney disease with CKD stage 4 or higher (eGFR<29)
•(11) Those receiving fibrates, immunosuppressants, or nicotinic acid
•(12) Those with untreated hypothyroidism (excluding subclinical hypothyroidism),
•(13) Those with hereditary myopathy or family history of hereditary myopathy
•(14) Those with history of drug-induced myopathy
•(15) Those with peptic ulcer
•(16) Those with bleeding tendency (except due to side effects of aspirin)
•(17) Those with aspirin asthma or a history of aspirin asthma
•(18) Those deemed by the principal investigator or co-investigator to be inappropriate to participate in this study

发起方

Kumasawa Keiichi